Loren Bass
Family · Centre, ALNPI 1114224854
Payments from drug & device makers
Across 217 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$671
- AbbVie$503
- Lilly USA, LLC$295
- Pfizer$218
- AstraZeneca$210
- Merck$170
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,218100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,218 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 73 | $98,064 |
| OzempicSemaglutide | 78 | $81,156 |
| FarxigaDapagliflozin Propanediol | 43 | $58,663 |
| JardianceEmpagliflozin | 36 | $44,458 |
| TrulicityDulaglutide | 27 | $35,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $33,990 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $32,352 |
| EliquisApixaban | 38 | $30,596 |
| JanuviaSitagliptin Phosphate | 24 | $22,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $21,865 |
| LinzessLinaclotide | 17 | $18,164 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $12,952 |
| TradjentaLinagliptin | 21 | $12,829 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $12,440 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $11,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $295 | $133,726100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $210 | $88,38199 claims |
| Novo NordiskOzempic | $124 | $81,15678 claims |
| Boehringer IngelheimJardiance, Tradjenta | $27 | $57,28657 claims |
| GSKTrelegy Ellipta | $671 | $33,99048 claims |
| PfizerEliquis | $218 | $30,59638 claims |
| MerckJanuvia | $170 | $22,92224 claims |
| AbbVieLinzess, Synthroid | $503 | $19,70328 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $7,81713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Centre
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.